Key Points
-
Clinical Parkinson disease (cPD) is associated with both distributed Lewy pathology (LP) and neuronal death. There are no proven strategies of modifying either feature of the disease.
-
Although there is consistency in the brain regions manifesting LP, there is considerable variability in its sequencing and severity. Moreover, the relationship between LP and the pathophysiology underlying symptoms is uncertain.
-
The distribution of LP in cPD is not consistent with a simple prion model in which the spread of LP is retrograde and determined solely by the brain connectome.
-
Neuronal death in cPD is less well characterized, but it is seen first in the substantia nigra, appearing later in a subset of neurons in the diencephalon, telencephalon and brainstem. Importantly, the pattern of neuronal death differs considerably in staging and to a lesser extent in distribution from that of LP.
-
Many of the neurons that die in cPD exhibit a common set of traits, which include a long, highly branched axon, autonomous spiking, elevated calcium entry and basal mitochondrial oxidant stress. This set of traits may make these neurons vulnerable to cell death in association with LP, ageing, genetic mutations associated with cPD and/or environmental toxins.
-
Therapeutic strategies aimed at altering the features of neurons that make them vulnerable to death and LP have the potential to slow or stop the progression of cPD.
Abstract
Intracellular α-synuclein (α-syn)-rich protein aggregates called Lewy pathology (LP) and neuronal death are commonly found in the brains of patients with clinical Parkinson disease (cPD). It is widely believed that LP appears early in the disease and spreads in synaptically coupled brain networks, driving neuronal dysfunction and death. However, post-mortem analysis of human brains and connectome-mapping studies show that the pattern of LP in cPD is not consistent with this simple model, arguing that, if LP propagates in cPD, it must be gated by cell- or region-autonomous mechanisms. Moreover, the correlation between LP and neuronal death is weak. In this Review, we briefly discuss the evidence for and against the spreading LP model, as well as evidence that cell-autonomous factors govern both α-syn pathology and neuronal death.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Berg, D. et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson's disease. Mov. Disord. 29, 454–462 (2014). This article reviews clinical and biological knowledge on PD showing that LP is not essential for cPD and occurs in a large proportion of patients who may not have cPD.
Hornykiewicz, O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov. Disord. 17, 501–508 (2002).
Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13–24 (2012).
Dijkstra, A. A. et al. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Mov. Disord. 29, 1244–1251 (2014). This paper describes a negative correlation between neuronal density and local α-syn burden in the SN of patients with PD and shows that the severity of neurodegeneration and local burden of α-syn pathological conditions are closely coupled during disease progression.
Hawkes, C. H., Del Tredici, K. & Braak, H. Parkinson's disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33, 599–614 (2007).
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121–134 (2004). This seminal paper reviews the evidence supporting the notion that LP is distributed and staged in PD.
Beach, T. G. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613–634 (2009).
Del Tredici, K., Rüb, U., de Vos, R. A., Bohl, J. R. & Braak, H. Where does parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61, 413–426 (2002).
Kosaka, K., Yoshimura, M., Ikeda, K. & Budka, H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree — a new disease? Clin. Neuropathol. 3, 185–192 (1984).
Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M. & Pearce, R. K. B. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α-synuclein staging. Neuropathol. Appl. Neurobiol. 34, 284–295 (2008).
Halliday, G., McCann, H. & Shepherd, C. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Expert Rev. Neurother. 12, 673–686 (2012). This review evaluates the main elements underpinning the Braak hypothesis of propagation, comparing data for both PD and the similar pathological entity of dementia with Lewy bodies, as well as data using cohorts with potential prodromal features of PD.
Doherty, K. M. et al. Parkin disease: a clinicopathologic entity? JAMA Neurol. 70, 571–579 (2013).
Kingsbury, A. E. et al. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov. Disord. 25, 2508–2515 (2010).
Dugger, B. N. & Dickson, D. W. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol. 120, 633–639 (2010).
Braak, H. & Del Tredici, K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv. Anat. Embryol. Cell Biol. 201, 1–119 (2009).
Li, J.-Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503 (2008).
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504–506 (2008).
Mendez, I. et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14, 507–509 (2008).
Kalia, L. V. & Kalia, S. K. α-Synuclein and Lewy pathology in Parkinson's disease. Curr. Opin. Neurol. 28, 375–381 (2015).
Kirik, D. et al. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780–2791 (2002).
Kirik, D. et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 2884–2889 (2003).
Maingay, M., Romero-Ramos, M., Carta, M. & Kirik, D. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol. Dis. 23, 522–532 (2006).
Ulusoy, A. et al. Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol. Med. 5, 1051–1059 (2013).
Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953 (2012). This was the first demonstration that pre-formed α-syn fibrils can propagate from one neuron to another and induce cell death in vivo when inoculated into the brain of mice.
Masuda-Suzukake, M. et al. Prion-like spreading of pathological α-synuclein in brain. Brain 136, 1128–1138 (2013).
Peelaerts, W. et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340–344 (2015).
Rey, N. L. et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J. Exp. Med. 213, 1759–1778 (2016). This paper provides the first clear evidence of transneuronal propagation of pre-formed α-syn fibril-induced pathology from the olfactory bulb in mice.
Recasens, A. et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351–362 (2014). This paper used purified pathological α-syn from the SN of patients with PD to show the intracellular and presynaptic accumulation of endogenous α-syn and the progressive axon-initiated neurodegeneration.
Mao, X. et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).
Shrivastava, A. N. et al. α-Synuclein assemblies sequester neuronal α3-Na+/K+-ATPase and impair Na+ gradient. EMBO J. 34, 2408–2423 (2015).
Uchihara, T. & Giasson, B. I. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 131, 49–73 (2016). This review systematically evaluates data for and against the hypothesis that α-syn propagates in PD and other neurodegenerative disorders.
Walsh, D. M. & Selkoe, D. J. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 17, 251–260 (2016).
Sacino, A. N. et al. Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. J. Neurochem. http://dx.doi.org/10.1111/jnc.13743 (2016).
Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M.-Y. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135–2146 (2014).
Volpicelli-Daley, L. A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71 (2011).
Helwig, M. et al. Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice. Brain 139, 856–870 (2016). Using viral gene delivery of an α-syn expression construct to the vagus nerve, the authors examined the propagation of different forms of α-syn through the brainstem; they found that endogenous α-syn impeded, rather than promoted, the spread of oligomeric forms of α-syn.
Olanow, C. W. & Brundin, P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov. Disord. 28, 31–40 (2013).
Wall, N. R., Wickersham, I. R., Cetin, A., De La Parra, M. & Callaway, E. M. Monosynaptic circuit tracing in vivo through Cre-dependent targeting and complementation of modified rabies virus. Proc. Natl Acad. Sci. USA 107, 21848–21853 (2010).
Koch, C. & Reid, R. C. Neuroscience: observatories of the mind. Nature 483, 397–398 (2012).
Schwarz, L. A. et al. Viral-genetic tracing of the input–output organization of a central noradrenaline circuit. Nature 524, 88–92 (2015).
Ogawa, S. K., Cohen, J. Y., Hwang, D., Uchida, N. & Watabe-Uchida, M. Organization of monosynaptic inputs to the serotonin and dopamine neuromodulatory systems. Cell Rep. 8, 1105–1118 (2014).
Watabe-Uchida, M., Zhu, L., Ogawa, S. K., Vamanrao, A. & Uchida, N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74, 858–873 (2012).
Halliday, G. M., Song, Y. J. C. & Harding, A. J. Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease. J. Neural Transm. 118, 713–719 (2011).
Milber, J. M. et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 79, 2307–2314 (2012).
Damier, P., Hirsch, E. C., Agid, Y. & Graybiel, A. M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122, 1437–1448 (1999).
Halliday, G. M. et al. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J. Clin. Neurosci. 3, 52–60 (1996).
Halliday, G. M. et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27, 373–385 (1990).
Harding, A. J., Stimson, E., Henderson, J. M. & Halliday, G. M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125, 2431–2445 (2002).
Henderson, J. M., Carpenter, K., Cartwright, H. & Halliday, G. M. Degeneration of the centré median–parafascicular complex in Parkinson's disease. Ann. Neurol. 47, 345–352 (2000).
Thannickal, T. C. et al. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130, 1586–1595 (2007).
Fronczek, R. et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. Brain 131, e88 (2008).
Kremer, H. P. H. & Bots, G. T. A. M. Lewy bodies in the lateral hypothalamus: do they imply neuronal loss? Mov. Disord. 8, 315–320 (1993).
Jellinger, K. A. Formation and development of Lewy pathology: a critical update. J. Neurol. 256, 270–279 (2009).
Ansorge, O., Daniel, S. E. & Pearce, R. K. Neuronal loss and plasticity in the supraoptic nucleus in Parkinson's disease. Neurology 49, 610–613 (1997).
MacDonald, V. & Halliday, G. M. Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov. Disord. 17, 1166–1173 (2002).
Pedersen, K. M., Marner, L., Pakkenberg, H. & Pakkenberg, B. No global loss of neocortical neurons in Parkinson's disease: a quantitative stereological study. Mov. Disord. 20, 164–171 (2005).
Sara, S. J. & Bouret, S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neuron 76, 130–141 (2012).
Saper, C. B., Scammell, T. E. & Lu, J. Hypothalamic regulation of sleep and circadian rhythms. Nature 437, 1257–1263 (2005).
Pfaff, D. W., Martin, E. M. & Faber, D. Origins of arousal: roles for medullary reticular neurons. Trends Neurosci. 35, 468–476 (2012).
Aston-Jones, G. & Waterhouse, B. Locus coeruleus: from global projection system to adaptive regulation of behavior. Brain Res. 1645, 75–78 (2016).
Alexandre, C., Andermann, M. L. & Scammell, T. E. Control of arousal by the orexin neurons. Curr. Opin. Neurobiol. 23, 752–759 (2013).
Palmiter, R. D. Dopamine signaling as a neural correlate of consciousness. Neuroscience 198, 213–220 (2011).
Saper, C. B. The central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Annu. Rev. Neurosci. 25, 433–469 (2003).
Silvani, A., Calandra-Buonaura, G., Dampney, R. A. L. & Cortelli, P. Brain–heart interactions: physiology and clinical implications. Philos. Trans. A Math. Phys. Eng. Sci. 374, 20150181 (2016).
Miskovic, V. & Schmidt, L. A. Social fearfulness in the human brain. Neurosci. Biobehav. Rev. 36, 459–478 (2012).
Matsuda, W. et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 29, 444–453 (2009).
Martinez-Gonzalez, C., Bolam, J. P. & Mena-Segovia, J. Topographical organization of the pedunculopontine nucleus. Front. Neuroanat. 5, 22 (2011).
Hornung, J.-P. The human raphe nuclei and the serotonergic system. J. Chem. Neuroanat. 26, 331–343 (2003).
Ratcliffe, E. M., Farrar, N. R. & Fox, E. A. Development of the vagal innervation of the gut: steering the wandering nerve. Neurogastroenterol. Motil. 23, 898–911 (2011).
Baufreton, J. et al. Sparse but selective and potent synaptic transmission from the globus pallidus to the subthalamic nucleus. J. Neurophysiol. 102, 532–545 (2009).
Hu, B., Yang, N., Qiao, Q.-C., Hu, Z.-A. & Zhang, J. Roles of the orexin system in central motor control. Neurosci. Biobehav. Rev. 49, 43–54 (2015).
Liu, A. K. L., Chang, R. C.-C., Pearce, R. K. B. & Gentleman, S. M. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. Acta Neuropathol. 129, 527–540 (2015).
Bolam, J. P. & Pissadaki, E. K. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov. Disord. 27, 1478–1483 (2012).
Hunn, B. H. M., Cragg, S. J., Bolam, J. P., Spillantini, M. G. & Wade-Martins, R. Impaired intracellular trafficking defines early Parkinson's disease. Trends Neurosci. 38, 178–188 (2015). This review highlights the potential role of intracellular trafficking in PD pathogenesis, which is particularly important in view of the growing importance of RAB proteins.
Pacelli, C. et al. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr. Biol. 25, 2349–2360 (2015).
Zhou, F.-M., Wilson, C. J. & Dani, J. A. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J. Neurobiol. 53, 590–605 (2002).
Surmeier, D. J., Guzman, J. N., Sanchez, J. & Schumacker, P. T. Physiological phenotype and vulnerability in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2, a009290 (2012).
Nedergaard, S., Flatman, J. A. & Engberg, I. Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol. 466, 727–747 (1993).
Puopolo, M., Raviola, E. & Bean, B. P. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci. 27, 645–656 (2007).
Guzman, J. N., Sánchez-Padilla, J., Chan, C. S. & Surmeier, D. J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29, 11011–11019 (2009).
Mercuri, N. B. et al. Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br. J. Pharmacol. 113, 831–838 (1994).
Chan, C. S. et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447, 1081–1086 (2007).
Foehring, R. C., Zhang, X. F., Lee, J. C. F. & Callaway, J. C. Endogenous calcium buffering capacity of substantia nigral dopamine neurons. J. Neurophysiol. 102, 2326–2333 (2009).
Khaliq, Z. M. & Bean, B. P. Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J. Neurosci. 30, 7401–7413 (2010).
Philippart, F. et al. Differential somatic Ca2+ channel profile in midbrain dopaminergic neurons. J. Neurosci. 36, 7234–7245 (2016).
Sánchez-Padilla, J. et al. Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat. Neurosci. 17, 832–840 (2014).
Goldberg, J. A. et al. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat. Neurosci. 15, 1414–1421 (2012).
Kang, Y. & Kitai, S. T. Electrophysiological properties of pedunculopontine neurons and their postsynaptic responses following stimulation of substantia nigra reticulata. Brain Res. 535, 79–95 (1990).
Putzier, I., Kullmann, P. H. M., Horn, J. P. & Levitan, E. S. CaV1.3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J. Neurosci. 29, 15414–15419 (2009).
Guzman, J. N. et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696–700 (2010). This is the first demonstration that Ca2+ entry through Cav1 channels during pacemaking elevates mitochondrial oxidant stress in SN DA neurons; the authors examined ex vivo brain slices from young adult mice and also showed that this oxidant stress was exacerbated by deletion of the gene encoding protein deglycase DJ1.
Hayashi, T., Rizzuto, R., Hajnóczky, G. & Su, T.-P. MAM: more than just a housekeeper. Trends Cell Biol. 19, 81–88 (2009).
Balaban, R. S. The role of Ca2+ signaling in the coordination of mitochondrial ATP production with cardiac work. Biochim. Biophys. Acta 1787, 1334–1341 (2009).
Nicholls, D. G. Mitochondria in the life and death of neurons. Essays Biochem. 33, 43–52 (1998).
Dragicevic, E., Schiemann, J. & Liss, B. Dopamine midbrain neurons in health and Parkinson's disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience 284, 798–814 (2015).
Albin, R. L., Young, A. B. & Penney, J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366–375 (1989).
Gerfen, C. R. & Surmeier, D. J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 34, 441–466 (2011).
Votyakova, T. V. & Reynolds, I. J. Δψm-dependent and -independent production of reactive oxygen species by rat brain mitochondria. J. Neurochem. 79, 266–277 (2001).
Brimblecombe, K. R., Gracie, C. J., Platt, N. J. & Cragg, S. J. Gating of dopamine transmission by calcium and axonal N-, Q-, T- and L-type voltage-gated calcium channels differs between striatal domains. J. Physiol. 593, 929–946 (2015).
de Vries, R. L. A. & Przedborski, S. Mitophagy and Parkinson's disease: be eaten to stay healthy. Mol. Cell. Neurosci. 55, 37–43 (2013).
Wong, E. & Cuervo, A. M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13, 805–811 (2010).
Gupta, A., Dawson, V. L. & Dawson, T. M. What causes cell death in Parkinson's disease? Ann. Neurol. 64, S3–S15 (2009).
Nagley, P., Higgins, G. C., Atkin, J. D. & Beart, P. M. Multifaceted deaths orchestrated by mitochondria in neurones. Biochim. Biophys. Acta 1802, 167–185 (2010).
Rcom-H'cheo-Gauthier, A., Goodwin, J. & Pountney, D. L. Interactions between calcium and alpha-synuclein in neurodegeneration. Biomolecules 4, 795–811 (2014).
Nath, S., Goodwin, J., Engelborghs, Y. & Pountney, D. L. Raised calcium promotes α-synuclein aggregate formation. Mol. Cell. Neurosci. 46, 516–526 (2011).
Dufty, B. M. et al. Calpain-cleavage of α-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725–1738 (2007).
Diepenbroek, M. et al. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice. Hum. Mol. Genet. 23, 3975–3989 (2014).
Melachroinou, K. et al. Deregulation of calcium homeostasis mediates secreted α-synuclein-induced neurotoxicity. Neurobiol. Aging 34, 2853–2865 (2013).
Caraveo, G. et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. Proc. Natl Acad. Sci. USA 111, E3544–E3552 (2014).
Gómez-Sintes, R., Ledesma, M. D. & Boya, P. Lysosomal cell death mechanisms in aging. Ageing Res. Rev. 32, 150–168 (2016).
Reeve, A., Simcox, E. & Turnbull, D. Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res. Rev. 14, 19–30 (2014). This article summarizes and discusses how ageing might make SN neurons especially vulnerable to changes in protein metabolism and mitochondrial function.
Duda, J., Pötschke, C. & Liss, B. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. J. Neurochem. 139, 156–178 (2016).
Beilina, A. & Cookson, M. R. Genes associated with Parkinson's disease: regulation of autophagy and beyond. J. Neurochem. 139 (Suppl. 1), 91–107 (2015). The authors review the proposition that many known PD-related genes can be assigned to pathways that affect autophagy and mitochondrial quality control through mitophagy.
Cookson, M. R. α-Synuclein and neuronal cell death. Mol. Neurodegener. 4, 9 (2009).
Gegg, M. E. & Schapira, A. H. V. Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol. Dis. 90, 43–50 (2016).
Schneider, J. L. & Cuervo, A. M. Autophagy and human disease: emerging themes. Curr. Opin. Genet. Dev. 26, 16–23 (2014).
Jellinger, K. A. & Jellinger, K. A. A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta 1792, 730–740 (2009). This review summarizes the deviation from the Braak staging model and the difficulty oflinking LP and disease symptom severity.
Sulzer, D. & Surmeier, D. J. Neuronal vulnerability, pathogenesis, and Parkinsons disease. Mov. Disord. 28, 715–724 (2013).
Pissadaki, E. K. & Bolam, J. P. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front. Comput. Neurosci. 7, 13 (2013).
Liss, B. & Roeper, J. Individual dopamine midbrain neurons: functional diversity and flexibility in health and disease. Brain Res. Rev. 58, 314–321 (2008).
German, D. C., Manaye, K. F., Sonsalla, P. K. & Brooks, B. A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. NY Acad. Sci. 648, 42–62 (1992).
Dopeso-Reyes, I. G. et al. Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques. Front. Neuroanat. 8, 146 (2014).
McCormack, A. L., Atienza, J. G., Langston, J. W. & Di Monte, D. A. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience 141, 929–937 (2006).
Bender, A. et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515–517 (2006).
Bender, A. et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J. Neurol. 255, 1231–1235 (2008).
Roberts, H. L. & Brown, D. R. Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules 5, 282–305 (2015). This review nicely summarizes the literature linking α-syn and neuronal toxicity.
Halliday, G., Hely, M., Reid, W. & Morris, J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 115, 409–415 (2008).
Petit, G. H., Olsson, T. T. & Brundin, P. The future of cell therapies and brain repair: Parkinson's disease leads the way. Neuropathol. Appl. Neurobiol. 40, 60–70 (2014).
Brundin, P. & Kordower, J. H. in Functional Neural Transplantation III — Primary and Stem Cell Therapies for Brain Repair, Part I (eds Dunnett, S. B. & Bjorklund, A.) 221–241 (Elsevier, 2012).
Li, J.-Y. et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 25, 1091–1096 (2010).
Brini, M., Calì, T., Ottolini, D. & Carafoli, E. Neuronal calcium signaling: function and dysfunction. Cell. Mol. Life Sci. 71, 2787–2814 (2014).
Guardia-Laguarta, C., Area-Gomez, E., Schon, E. A. & Przedborski, S. A new role for α-synuclein in Parkinson's disease: alteration of ER-mitochondrial communication. Mov. Disord. 30, 1026–1033 (2015). This review advances thenovel concept that α-syn affects neuronal function by modulating endoplasmic reticulum–mitochondrial crosstalk.
McCoy, M. K. & Cookson, M. R. Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid. Redox Signal. 16, 869–882 (2012).
Dryanovski, D. I. et al. Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 33, 10154–10164 (2013).
Mosharov, E. V. et al. Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 62, 218–229 (2009).
Subramaniam, M. et al. Mutant α-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels. J. Neurosci. 34, 13586–13599 (2014).
Brichta, L. et al. Identification of neurodegenerative factors using translatome-regulatory network analysis. Nat. Neurosci. 18, 1325–1333 (2015).
Poulin, J.-F. et al. Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling. Cell Rep. 9, 930–943 (2014).
Murchison, D. & Griffith, W. H. Calcium buffering systems and calcium signaling in aged rat basal forebrain neurons. Aging Cell 6, 297–305 (2007).
Hafkemeijer, A., van der Grond, J. & Rombouts, S. A. R. B. Imaging the default mode network in aging and dementia. Biochim. Biophys. Acta 1822, 431–441 (2012).
Hammond, C., Bergman, H. & Brown, P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci. 30, 357–364 (2007).
Thibault, O., Gant, J. C. & Landfield, P. W. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 6, 307–317 (2007).
Hurley, M. J., Gentleman, S. M. & Dexter, D. T. Calcium CaV1 channel subtype mRNA expression in Parkinson's disease examined by in situ hybridization. J. Mol. Neurosci. 55, 1–10 (2014).
Hurley, M. J., Brandon, B., Gentleman, S. M. & Dexter, D. T. Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136, 2077–2097 (2013).
Ilijic, E., Guzman, J. N. & Surmeier, D. J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 43, 364–371 (2011).
Kupsch, A. et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 741, 185–196 (1996).
Singh, A., Verma, P., Balaji, G., Samantaray, S. & Mohanakumar, K. P. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neurochem. Int. 99, 221–232 (2016).
Lee, Y.-C. et al. Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study. PLoS ONE 9, e98961 (2014).
Pasternak, B. et al. Use of calcium channel blockers and Parkinson's disease. Am. J. Epidemiol. 175, 627–635 (2012).
Marras, C. et al. Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann. Neurol. 71, 362–369 (2012).
Ritz, B. et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600–606 (2010).
Becker, C., Jick, S. S. & Meier, C. R. Use of antihypertensives and the risk of Parkinson disease. Neurology 70, 1438–1444 (2008).
Gudala, K., Kanukula, R. & Bansal, D. Reduced risk of Parkinson's disease in users of calcium channel blockers: a meta-analysis. Int. J. Chron. Dis. 2015, 697404 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/record/NCT02168842 (2016).
Mullin, S. & Schapira, A. The genetics of Parkinson's disease. Br. Med. Bull. 114, 39–52 (2015). This article reviews the role of genome-wide association studies in deciphering inter-related genetic mechanisms and biochemical pathways.
Lin, M. K. & Farrer, M. J. Genetics and genomics of Parkinson's disease. Genome Med. 6, 48 (2014).
Kumaran, R. & Cookson, M. R. Pathways to parkinsonism redux: convergent pathobiological mechanisms in genetics of Parkinson's disease. Hum. Mol. Genet. 24, R32–R44 (2015).
Poulopoulos, M., Levy, O. A. & Alcalay, R. N. The neuropathology of genetic Parkinson's disease. Mov. Disord. 27, 831–842 (2012).
Konno, T., Ross, O. A., Puschmann, A., Dickson, D. W. & Wszolek, Z. K. Autosomal dominant Parkinson's disease caused by SNCA duplications. Parkinsonism Relat. Disord. 22 (Suppl. 1), 1–6 (2016).
Cuervo, A. M. & Wong, E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 24, 92–104 (2014).
Ryan, B. J., Hoek, S., Fon, E. A. & Wade-Martins, R. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem. Sci. 40, 200–210 (2015).
Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S. & Selkoe, D. J. Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 289, 21490–21507 (2014).
Calì, T., Ottolini, D., Negro, A. & Brini, M. α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 287, 17914–17929 (2012).
Guardia-Laguarta, C., Area-Gomez, E., Schon, E. A. & Przedborski, S. Novel subcellular localization for α-synuclein: possible functional consequences. Front. Neuroanat. 9, 17 (2015).
Cookson, M. R. LRRK2 pathways leading to neurodegeneration. Curr. Neurol. Neurosci. Rep. 15, 564–510 (2015).
Esteves, A. R., Swerdlow, R. H. & Cardoso, S. M. LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp. Neurol. 261, 206–216 (2014).
Martin, I., Kim, J. W., Dawson, V. L. & Dawson, T. M. LRRK2 pathobiology in Parkinson's disease. J. Neurochem. 131, 554–565 (2014).
Kalia, L. V. et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 72, 100–105 (2015).
Bonifati, V. Autosomal recessive parkinsonism. Parkinsonism Relat. Disord. 18 (Suppl. 1), S4–S6 (2012).
Zucca, F. A. et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog. Neurobiol. http://dx.doi.org/10.1016/j.pneurobio.2015.09.012 (2015).
Kirkwood, T. B. L. Global aging and the brain. Nutr. Rev. 68 (Suppl. 2), 65–69 (2010).
Sahin, E. & DePinho, R. A. Axis of ageing: telomeres, p53 and mitochondria. Nat. Rev. Mol. Cell Biol. 13, 397–404 (2012).
Collier, T. J., Kanaan, N. M. & Kordower, J. H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 12, 359–366 (2011).
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003).
Acknowledgements
This work was supported by US National Institutes of Health grant NS047085 and grants from the JPB Foundation and the IDP Foundation (to D.J.S.). G.M.H. is a National Health and Medical Research Council of Australia Senior Principal Research Fellow (grant #1079679). J.A.O.'s research is supported by grants SAF2012-40216 and SAF2015-67239-P from the Plan Nacional, Ministerio de Economía y Competitividad, Spain.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- Lewy pathology
-
(LP). Abnormal, proteinaceous aggregates in the neuronal cytoplasm that are rich in α-synuclein.
- Connectome
-
A detailed map of the synaptic connections that are formed between neurons in the brain.
- Levodopa
-
The precursor to the neurotransmitter dopamine; it is given to patients with Parkinson disease because, unlike dopamine, it can pass through the blood–brain barrier and elevate brain dopamine concentrations.
- Lewy neurites
-
Lewy pathology found within neuronal processes, including axons and dendrites.
- Mitophagy
-
A form of autophagy in which damaged mitochondria are degraded.
- Apoptosis
-
A process of programmed cell death involving activation of caspase signalling cascades that are commonly triggered by release of cytochrome c from mitochondria.
- Necrosis
-
A form of cell death that is distinct from apoptosis and that is commonly caused by infection, toxins or ischaemia.
- Mitochondrial redox
-
The state of reduction–oxidation reactions in mitochondria.
- Phenocopies
-
In this case, neurons with a similar set of traits (for example, activity patterns) resulting from the interaction between their genome and the environment.
- Dihydropyridine
-
A class of US-approved drugs that are negative allosteric modulators of Ca2+ channels with a Cav1 pore-forming subunit.
Rights and permissions
About this article
Cite this article
Surmeier, D., Obeso, J. & Halliday, G. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 18, 101–113 (2017). https://doi.org/10.1038/nrn.2016.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrn.2016.178
This article is cited by
-
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
Molecular Neurodegeneration (2024)
-
Intravitreal MPTP drives retinal ganglion cell loss with oral nicotinamide treatment providing robust neuroprotection
Acta Neuropathologica Communications (2024)
-
Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson’s disease
Cell Communication and Signaling (2024)
-
Precision drug delivery to the central nervous system using engineered nanoparticles
Nature Reviews Materials (2024)
-
Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease
npj Parkinson's Disease (2024)